Effect of antisecretory treatment on gastrointestinal microbiota

Румянцева, Д. Е.; Трухманов, А. С.; Кудрявцева, А. В.; Ивашкин, В. Т.

doi:10.22416/1382-4376-2018-28-1-78-88

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seto C. T. с соавт. [33] также обнаружили значительное уменьшение микробного пейзажа у здоровых участников исследования, принимавших ИПП в течение 28 дней [32]. При этом исследование Del Piano с соавт.…”

Section: влияние антисекреторных препаратов на микробиом кишечникаunclassified

Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis

Бакулин

Serkova

2023

jour

View full text Add to dashboard Cite

The review presents up-to-date information on the pathogenesis of disorders of the intestinal microbiotope and the relationship of these disorders with the use of medications traditionally prescribed in treatment regimens for various diseases, presents the main aspects of drug-microbial interactions, highlights the issues of correction of iatrogenic intestinal dysbiosis. One of the main exogenous factors in the development of intestinal dysbiosis at the present time, of course, can be considered drug therapy. The extremely widespread and often uncontrolled use of antibacterial drugs, nonsteroidal anti-inflammatory drugs, laxatives, drugs for the correction of carbohydrate metabolism, proton pump inhibitors, glucocorticosteroids, antidepressants, cytostatic drugs to a greater or lesser extent has a negative effect on the human microbiotope. On the one hand, the microbiota is a drug target, on the other hand, the gut microbiota itself can have both direct and indirect effects on the metabolism of drugs. The potential of the influence of microorganisms on the absorption, distribution, and metabolism of drugs deserves increased attention and detailed study. At the same time, the issues of prevention and correction of intestinal microbiota disorders against the background of taking various medications deserve even more attention from doctors of various profiles with the mandatory inclusion of drugs that harmonize the intestinal microbiotope in the treatment regimens of the underlying disease.

show abstract

Section: влияние антисекреторных препаратов на микробиом кишечникаunclassified

Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis

Бакулин

Serkova

2023

jour

View full text Add to dashboard Cite

show abstract

“…С одной стороны, муцины выполняют барьерную функцию: образуют защитный слой между микробиотой и иммунными клетками слизистой оболочки органов ЖКТ и препятствуют нежелательному взаимодействию с патогенными микроорганизмами. С другой стороны, муцины выполняют «пребиотическую» функцию: обеспечивают начальный этап адгезии, создают субстратное обеспечение эпителиоцитов и матрицу, на которой бактерии могут размножаться и существовать [24].…”

unclassified

“…Таким образом, выявление особенностей взаимосвязи микробиоты верхних отделов ЖКТ, количественного и качественного состава слизи и муцинов слизистой оболочки, уровня рН представляет большой интерес для понимания механизмов развития и прогрессирования кислотозависимых заболеваний и позволяет определить дополнительные терапевтические возможности влияния на защитные свойства слизистой оболочки, в том числе при терапии ИПП [24].…”

unclassified

Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)

Ивашкин

Маев

Трухманов

et al. 2020

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Aim. Presentation of the Forum “Deprescribing and optimal selection of proton pump inhibitors” held in Moscow on 29 September 2020 during the 26th United Russian Gastroenterology Week.Key points. The Forum was aimed at discussing issues associated with improving the proton pump inhibitor (PPIs) therapy in treatment and prevention of acid-related diseases and upper gastrointestinal tract (GIT) disorders induced by non-steroidal anti-inﬂammatory drugs (NSAIDs) and antiplatelet medications. Deprescribing is considered to be an eﬀective strategy of a motivated reduction of the PPI dosage, duration of therapy and the patient’s transfer from a regular to on-demand intake regimen. The choice of PPI may condition an optimal therapy for acid-related diseases.Conclusion. PPIs prevail in therapies for acid-related diseases and NSAID-induced upper GIT lesions. PPI deprescribing should be a strategy of choice if medically indicated. A non-enzymatic metabolism, high acid suppression, stable antisecretory eﬀect from day 1 of therapy and cytoprotective action justify the application of rabeprazole (Pariet®) for optimising therapies for acid-related diseases and implementing the deprescribing strategy.

show abstract

“…Микробиота пищевода у здоровых добровольцев, больных с ГЭРБ и пищеводом Барретта по данным различных авторов[16] Esophageal microbiota of healthy volunteers, patients with GERD and Barrett's esophagus according to different authors[16] …”

unclassified

Microbiota of the Esophagus and Stomach in Patients with Gastroesophageal Reflux Disease and Healthy Volunteers

Румянцева¹,

Трухманов²,

Кудрявцева³

et al. 2018

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

This paper is aimed at investigating the microbiota of the esophagus and stomach in patients with gastroesophageal reflux disease (GERD) and healthy volunteers.Materials and methods. The study included 15 patients suffering from GERD and 6 healthy volunteers. All subjects underwent sampling of esophageal and gastric contents. The study of the microbiota in the obtained samples was performed by sequencing the 16S gene of ribosomal RNA (rRNA).Results. The most common types of bacteria in the esophagus and stomach in patients with GERD and healthy volunteers are found to be Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, Fusobacterium. By comparing the relative contents of the main types of bacteria in the esophageal mucus and gastric contents, a significant decrease in the proportion of Proteobacteria was observed in patients with GERD as compared to healthy volunteers. The decrease in the relative number of bacteria belonging to the Acetobacteraceae, Bacillaceae, Bdellovibrionaceae, Clostridiales Insertae Sedis XI, Fusobacteriaceae, Moraxellaceae, Pasteurellaceae and Rhodocyclaceae families was observed in the esophagus in patients with GERD as compared to healthy volunteers. A higher bacterial content of the Leptotrichiaceae and Veillonellaceae families was detected in the stomach of patients with GERD.Conclusions. The obtained results indicate differences in the intraluminal microbiota of the esophagus and stomach in patients with GERD and healthy volunteers. Further study should be carried out to study the effect of changes in bacterial composition on those in the esophagus and stomach.

show abstract

Effect of antisecretory treatment on gastrointestinal microbiota

Cited by 3 publications

References 0 publications

Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis

Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis

Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)

Microbiota of the Esophagus and Stomach in Patients with Gastroesophageal Reflux Disease and Healthy Volunteers

Contact Info

Product

Resources

About